Drug Trial Radar · NCT01675297
Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis
Last checked: Nov 20, 2026Latest source record: Aug 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,053
Actual
Start
Jul 4, 2011
Primary completion
Dec 2013
Study completion Apr 15, 2014
Sponsor
- Lead sponsor
- Hanlim Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 29, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis.
Conditions
- Osteoporosis
Interventions
Risedronate/Cholecalciferol combinationDrug
Risendronate/Cholecalciferol combination once a week
RisedronateDrug
Risedronate once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change of Bone Mineral Density (BMD) ValueTime frame: baseline and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chung-ang university hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.